Coronary Artery Disease Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Coronary Artery Disease Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description

1
1

Coronary artery disease (CAD) is a common type of heart disease. Coronary heart disease occurs when there is less blood flow in the arteries of the heart and the arteries get narrowed due to formation of cholesterol and plaque. Coronary artery disease leads to angina or a heart attack. Over the time, coronary artery disease can also lead to permanent heart damage, heart failure, or arrhythmias.

Based on treatment type, the global coronary artery disease therapeutics market can be segmented into drugs, surgery, cardiac rehabilitation, and angioplasty. The drugs segment is likely to expand at a significant pace during the forecast period compared to other segments, due to extensive use of different classes of drugs in the treatment of coronary artery disease. Furthermore, the drugs segment can be sub-divided into beta blockers, calcium channel blockers, statin, and antiplatelet drugs. The antiplatelet drugs sub-segment is likely to expand at a high rate between 2017 and 2025, as antiplatelet drugs are highly effective in treating arterial clots that are generally composed of blood platelets. Based on test type, the coronary artery disease therapeutics market can be segmented into cardiac catheterization test, cardiac CT scan, coronary angiography, and electrocardiogram. The coronary angiography segment is expanding at a high growth rate, as the test helps the physician identify exact location of the disease in the heart and its severity. Also, the test procedure takes only 20 to 30 minutes to complete. Moreover, increasing number of Cath labs, growing obese population, rising number of smokers, and surging number of diabetes patients are factors driving the global market for coronary artery disease therapeutics. According to the World Health Organization, in 2015, almost 7.4 million people across the globe died of coronary heart diseases. However, inadequate health care facilities, drug courses with long duration, and high cost of surgery and devices (such as atherectomy device) in developing countries are restraining the coronary artery disease therapeutics market in these countries.

In terms of region, the global coronary artery disease therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market. North America is projected to hold a significant share of the global market, due to increasing number of cardiovascular disease patients, improved health care facilities, and increasing geriatric population with diabetes in the region. Moreover, according to the Centers for Diseases Control & Prevention, every year, more than 735,000 people in the U.S. suffer a heart attack. Growing use of drugs, increasing adoption of different atherectomy devices for advanced health care, and rising awareness regarding the treatment of coronary artery disease are factors that boost the market in Europe. Increasing pollution, rising number of smokers, and growing prevalence of heart diseases in Asia Pacific are likely to propel the coronary artery disease therapeutics market in the region during the forecast period. The Global Cardiovascular Community states that 27.7% of the adult population in Latin America was affected with heart diseases in 2016 and the rate is increasing. This is expected to offer growth opportunities to the global coronary artery disease therapeutics market in the next few years. Advancements in surgeries, increasing per capita income, and growing incidence chronic heart diseases are likely to augment the market for coronary artery disease therapeutics in Middle East & Africa during the forecast period.

Major players operating in the global coronary artery disease therapeutics market are Astrazeneca, Gilead, Novartis, Pfizer Inc., Lupin Pharmaceuticals Inc., and Abbott Vascular.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market       

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients